<html><head></head><body><h1>Moxifloxacin (Systemic)</h1><p class="drug-subtitle"><b>Class:</b> Quinolones<br/>
<b>VA Class:</b> AM900<br/>
<b>Chemical Name:</b> (4aS-cis)-1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(octahydro-6H-pyrrolol[3,4-b]pyridin-6-yl)-4-oxo-3-quinolinecarboxylic acid monohydrochloride<br/>
<b>Molecular Formula:</b> C<sub>21</sub>H<sub>24</sub>FN<sub>3</sub>O<sub>4</sub><br/>
<b>CAS Number:</b> 186826-86-8<br/>
<b>Brands:</b> Avelox</p><ul class="ddc-anchor-links"><li>Uses</li>
<li>Dosage</li>
<li>Cautions</li>
<li>Interactions</li>
<li>Pharmacokinetics</li>
<li>Patient advice</li>
<li>Preparations</li></ul><h3>Warning</h3><ul>Serious Adverse Reactions
<li>
<p>Fluoroquinolones, including moxifloxacin, have been associated with disabling and potentially irreversible serious adverse reactions (e.g., tendinitis and tendon rupture, peripheral neuropathy, CNS effects) that have occurred together.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Discontinue immediately and avoid use of fluoroquinolones, including moxifloxacin, in patients who have experienced any of these serious adverse reactions.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Warnings under Cautions.)</p>
</li>
<li>
<p>Fluoroquinolones, including moxifloxacin, may exacerbate muscle weakness in patients with myasthenia gravis.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Avoid in patients with known history of myasthenia gravis.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Because of risk of serious adverse reactions, use moxifloxacin for treatment of acute bacterial sinusitis or acute bacterial exacerbations of chronic bronchitis <i>only</i> when no other treatment options available.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
</ul><p>Fluoroquinolones, including moxifloxacin, have been associated with disabling and potentially irreversible serious adverse reactions (e.g., tendinitis and tendon rupture, peripheral neuropathy, CNS effects) that have occurred together.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Discontinue immediately and avoid use of fluoroquinolones, including moxifloxacin, in patients who have experienced any of these serious adverse reactions.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Warnings under Cautions.)</p><p>Fluoroquinolones, including moxifloxacin, may exacerbate muscle weakness in patients with myasthenia gravis.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Avoid in patients with known history of myasthenia gravis.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Because of risk of serious adverse reactions, use moxifloxacin for treatment of acute bacterial sinusitis or acute bacterial exacerbations of chronic bronchitis <i>only</i> when no other treatment options available.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2>Introduction</h2><p>Antibacterial; fluoroquinolone.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="uses">Uses for Moxifloxacin (Systemic)</h2><h3>Respiratory Tract Infections</h3><p>Treatment of acute bacterial sinusitis caused by susceptible <i>Streptococcus pneumoniae</i>, <i>Haemophilus influenzae</i>, or <i>Moraxella catarrhalis</i>.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Treatment of acute bacterial exacerbations of chronic bronchitis caused by susceptible <i>S. pneumoniae</i>, <i>H. influenzae</i>, <i>H. parainfluenzae</i>, <i>Klebsiella pneumoniae</i>, <i>Staphylococcus aureus</i>, or <i>M. catarrhalis</i>.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p><i>Use for treatment of acute bacterial sinusitis or acute bacterial exacerbations of chronic bronchitis only when no other treatment options available.</i>&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;140&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;145&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; <i>Because systemic fluoroquinolones, including moxifloxacin, have been associated with disabling and potentially irreversible serious adverse reactions (e.g., tendinitis and tendon rupture, peripheral neuropathy, CNS effects) that can occur together in the same patient</i> (see Cautions)&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;140&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;145&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; <i>and because acute bacterial sinusitis and acute bacterial exacerbations of chronic bronchitis may be self-limiting in some patients,</i>&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; <i>risks of serious adverse reactions outweigh benefits of fluoroquinolones for patients with these infections.</i>&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;140&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;145&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Treatment of community-acquired pneumonia (CAP) caused by susceptible <i>S. pneumoniae</i> (including multidrug-resistant strains; MDRSP), <i>S. aureus</i> (methicillin-susceptible [oxacillin-susceptible] strains), <i>K. pneumoniae</i>, <i>H. influenzae</i>, <i>M. catarrhalis</i>, <i>Mycoplasma pneumoniae</i>, or <i>Chlamydophila pneumoniae</i> (formerly <i>Chlamydia pneumoniae</i>).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;53&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;512&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Select regimen for empiric treatment of CAP based on most likely pathogens and local susceptibility patterns; after pathogen is identified, modify to provide more specific therapy (pathogen-directed therapy).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;512&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Has been used for treatment of nosocomial pneumonia†.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;101&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Select regimen for empiric treatment of hospital-acquired pneumonia (HAP) not associated with mechanical ventilation or ventilator-associated pneumonia (VAP) based on local susceptibility data.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;315&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; If a fluoroquinolone used for initial empiric treatment of HAP or VAP, IDSA and ATS recommend ciprofloxacin or levofloxacin.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;315&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Consult current IDSA clinical practice guidelines available at [Web] for additional information on management of respiratory tract infections.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;315&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;512&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Skin and Skin Structure Infections</h3><p>Treatment of uncomplicated skin and skin structure infections (abscesses, furuncles, cellulitis, impetigo) caused by susceptible <i>S. aureus</i> (methicillin-susceptible [oxacillin-susceptible] strains) or <i>S. pyogenes</i> (group A β-hemolytic streptococci).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;13&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;543&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Treatment of complicated skin and skin structure infections caused by susceptible <i>S. aureus</i> (oxacillin-susceptible strains), <i>Escherichia coli</i>, <i>K. pneumoniae</i>, or <i>Enterobacter cloacae</i>.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;44&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;543&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Consult current IDSA clinical practice guidelines available at [Web] for additional information on management of skin and skin structure infections.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;543&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;544&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Intra-abdominal Infections</h3><p>Treatment of complicated intra-abdominal infections (including polymicrobial infections such as abscess) caused by susceptible <i>Bacteroides fragilis</i>, <i>B. thetaiotaomicron</i>, <i>Clostridium perfringens</i>, <i>Enterococcus faecalis</i>, <i>E. coli</i>, <i>Proteus mirabilis</i>, <i>S. anginosus</i>, <i>S. constellatus</i>, or <i>Peptostreptococcus</i>.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;32&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;708&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Has been recommended as one of several options for initial empiric treatment of mild to moderate, community-acquired intra-abdominal infections.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;708&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; IDSA states avoid moxifloxacin in patients who received a quinolone within the past 3 months and are likely to harbor <i>B. fragilis</i> since such strains likely to be resistant to the drug.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;708&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Consult current IDSA clinical practice guidelines available at [Web] for additional information on management of intra-abdominal infections.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;708&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Endocarditis</h3><p>Alternative for treatment of endocarditis† (native or prosthetic valve or other prosthetic material) caused by fastidious gram-negative bacilli known as the HACEK group (<i>Haemophilus</i>, <i>Aggregatibacter</i>, <i>Cardiobacterium hominis</i>, <i>Eikenella corrodens</i>, <i>Kingella</i>).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;450&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; AHA and IDSA recommend ceftriaxone (or other third or fourth generation cephalosporin),&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;450&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; but state that a fluoroquinolone (ciprofloxacin, levofloxacin, moxifloxacin) may be considered in patients who cannot tolerate cephalosporins.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;450&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Consultation with an infectious disease specialist recommended.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;450&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>GI Infections</h3><p>Alternative for treatment of campylobacteriosis† caused by susceptible <i>Campylobacter</i>.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;440&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Optimal treatment of campylobacteriosis in HIV-infected patients not identified.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;440&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Some clinicians withhold anti-infective treatment in those with CD4<sup>+</sup> T-cell counts &gt;200 cells/mm<sup>3</sup> and mild campylobacteriosis and initiate treatment if symptoms persist for more than several days.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;440&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; In those with mild to moderate campylobacteriosis, treatment with a fluoroquinolone (preferably ciprofloxacin or, alternatively, levofloxacin or moxifloxacin) or azithromycin is reasonable.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;440&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Modify anti-infective treatment based on results of in vitro susceptibility;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;440&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; resistance to fluoroquinolones reported in 22% of <i>C. jejuni</i> and 35% of <i>C. coli</i> isolates tested in the US.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;440&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Treatment of <i>Salmonella</i> gastroenteritis†.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;440&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; CDC, NIH, and HIV Medicine Association of IDSA recommend ciprofloxacin as initial drug of choice for treatment of <i>Salmonella</i> gastroenteritis (with or without bacteremia) in HIV-infected adults;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;440&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; other fluoroquinolones (levofloxacin, moxifloxacin) also likely to be effective, but data limited.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;440&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Depending on in vitro susceptibility, alternatives are co-trimoxazole and third generation cephalosporins (ceftriaxone, cefotaxime).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;440&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Role of long-term anti-infective treatment (secondary prophylaxis) against <i>Salmonella</i> in HIV-infected individuals with recurrent bacteremia or gastritis not well established;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;440&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; weigh benefits of such prophylaxis against risks of long-term anti-infective therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;440&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Treatment of shigellosis† caused by susceptible <i>Shigella</i>.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;440&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Anti-infectives may not be required for mild infections, but generally indicated in addition to fluid and electrolyte replacement for treatment of patients with severe shigellosis, dysentery, or underlying immunosuppression.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;292&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;440&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Empiric treatment regimen can be used initially, but in vitro susceptibility testing indicated since resistance is common.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;292&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Fluoroquinolones (preferably ciprofloxacin or, alternatively, levofloxacin or moxifloxacin) have been recommended for treatment of shigellosis in HIV-infected adults, but consider that fluoroquinolone-resistant <i>Shigella</i> reported in the US, especially in international travelers, the homeless, and men who have sex with men (MSM).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;440&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Depending on in vitro susceptibility, other drugs recommended for treatment of shigellosis include co-trimoxazole, ceftriaxone, azithromycin (not recommended in those with bacteremia), or ampicillin.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;440&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Anthrax</h3><p>Alternative for postexposure prophylaxis of anthrax† following suspected or confirmed exposure to aerosolized <i>Bacillus anthracis</i> spores (inhalational anthrax).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;668&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;672&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;673&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;683&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; CDC, AAP, US Working Group on Civilian Biodefense, and US Army Medical Research Institute of Infectious Diseases (USAMRIID) recommend oral ciprofloxacin and oral doxycycline as initial drugs of choice for prophylaxis following such exposures, including exposures that occur in the context of biologic warfare or bioterrorism.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;668&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;671&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;672&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;673&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;683&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;686&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Other oral fluoroquinolones (levofloxacin, moxifloxacin, ofloxacin) are alternatives when ciprofloxacin or doxycycline cannot be used.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;668&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;671&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;672&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;673&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Treatment of uncomplicated cutaneous anthrax† (without systemic involvement) that occurs in the context of biologic warfare or bioterrorism.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;672&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;673&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; CDC states that preferred drugs for such infections include ciprofloxacin, doxycycline, levofloxacin, or moxifloxacin.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;672&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;673&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Alternative to ciprofloxacin for use in multiple-drug parenteral regimen for initial treatment of systemic anthrax† (inhalational, GI, meningitis, or cutaneous with systemic involvement, head or neck lesions, or extensive edema) that occurs in the context of biologic warfare or bioterrorism.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;671&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;672&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;673&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; For initial treatment of systemic anthrax with possible or confirmed meningitis, CDC and AAP recommend a regimen of IV ciprofloxacin in conjunction with another IV bactericidal anti-infective (preferably meropenem) and an IV protein synthesis inhibitor (preferably linezolid).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;671&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;672&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;673&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; If meningitis excluded, these experts recommend an initial regimen of IV ciprofloxacin in conjunction with an IV protein synthesis inhibitor (preferably clindamycin or linezolid).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;671&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;672&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;673&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Has been suggested as possible alternative to ciprofloxacin for treatment of inhalational anthrax† when a parenteral regimen not available (e.g., supply or logistic problems because large numbers of individuals require treatment in a mass casualty setting).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;668&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;683&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Meningitis and Other CNS Infections</h3><p>Alternative for treatment of meningitis† caused by certain susceptible gram-positive bacteria (e.g., <i>S. pneumoniae</i>).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;416&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;418&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Fluoroquinolones have been recommended as alternatives for treatment of meningitis caused by some gram-negative bacteria (e.g., <i>Neisseria meningitidis</i>, <i>H. influenzae</i>, <i>E. coli</i>, <i>Ps. aeruginosa</i>).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;416&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;418&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Limited data from animal studies indicate moxifloxacin has been effective for treatment of experimental meningitis caused by <i>S. pneumoniae</i> or <i>E. coli</i>.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;48&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;49&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Fluoroquinolones (ciprofloxacin, moxifloxacin) should be considered for treatment of meningitis only when the infection is caused by multidrug-resistant gram-negative bacilli or when the usually recommended anti-infectives cannot be used or have been ineffective.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;416&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;418&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Tuberculosis</h3><p>Alternative (second-line) agent for use in multiple-drug regimens for treatment of active tuberculosis† caused by <i>Mycobacterium tuberculosis</i>.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;218&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;231&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;276&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;440&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Although potential role of fluoroquinolones and optimal length of therapy not fully defined, ATS, CDC, IDSA, and others state that use of fluoroquinolones as alternative (second-line) agents can be considered for treatment of active tuberculosis in patients intolerant to certain first-line agents and in those with relapse, treatment failure, or <i>M. tuberculosis</i> resistant to certain first-line agents.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;218&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;231&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;276&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;440&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; If a fluoroquinolone used in multiple-drug regimens for treatment of active tuberculosis, ATS, CDC, IDSA, and others recommend levofloxacin or moxifloxacin.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;218&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;231&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;276&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;440&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Consider that fluoroquinolone-resistant <i>M. tuberculosis</i> reported and there are increasing reports of extensively drug-resistant tuberculosis (XDR tuberculosis).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;64&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;72&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; XDR tuberculosis is caused by <i>M. tuberculosis</i> resistant to rifampin and isoniazid (multiple-drug resistant strains) that also are resistant to a fluoroquinolone and at least one parenteral second-line antimycobacterial (capreomycin, kanamycin, amikacin).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;64&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;72&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Consult most recent ATS, CDC, and IDSA recommendations for treatment of tuberculosis and other mycobacterial infections for more specific information.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;218&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;440&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Other Mycobacterial Infections</h3><p>Has been used in multiple-drug regimens for treatment of disseminated infections caused by <i>Mycobacterium avium</i> complex† (MAC).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;440&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; ATS and IDSA state that role of fluoroquinolones in treatment of MAC infections not established.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;675&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; If a fluoroquinolone is included in treatment regimen (e.g., for macrolide-resistant MAC infections), moxifloxacin or levofloxacin may be preferred,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;440&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;675&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; although many strains are resistant in vitro.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;675&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Treatment of MAC infections is complicated and should be directed by clinicians familiar with mycobacterial diseases; consultation with a specialist is particularly important when the patient cannot tolerate first-line drugs or when the infection has not responded to prior therapy or is caused by macrolide-resistant MAC.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;675&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Treatment of <i>M. kansasii</i>† infections in conjunction with other antimycobacterials.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;675&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; ATS and IDSA recommend a multiple-drug regimen of isoniazid, rifampin, and ethambutol for treatment of pulmonary or disseminated infections caused by <i>M. kansasii</i>.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;675&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; If rifampin-resistant <i>M. kansasii</i> are involved, ATS and IDSA recommend a 3-drug regimen based on results of in vitro susceptibility testing, including clarithromycin (or azithromycin), moxifloxacin, ethambutol, sulfamethoxazole, or streptomycin.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;675&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Consult most recent ATS, CDC, and IDSA recommendations for treatment of other mycobacterial infections for more specific information.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;440&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;675&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Nongonococcal Urethritis</h3><p>Alternative for treatment of nongonococcal urethritis† (NGU).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;344&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; CDC recommends azithromycin or doxycycline;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;344&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; alternatives are erythromycin, levofloxacin, or ofloxacin.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;344&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; For persistent or recurrent NGU in men compliant with previous treatment who have not been reexposed to an untreated sexual partner(s), CDC recommends that those initially treated with azithromycin be retreated with moxifloxacin.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;344&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Plague</h3><p>Treatment of plague, including pneumonic and septicemic plague, caused by <i>Yersinia pestis</i>.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Streptomycin (or gentamicin) historically has been considered regimen of choice for treatment of plague;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;197&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;292&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;683&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;688&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; alternatives are doxycycline (or tetracycline), chloramphenicol (a drug of choice for plague meningitis), fluoroquinolones (ciprofloxacin [a drug of choice for plague meningitis], levofloxacin, moxifloxacin), or co-trimoxazole (may be less effective than other alternatives).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;197&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;292&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;683&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;688&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Regimens recommended for treatment of naturally occurring or endemic bubonic, septicemic, or pneumonic plague also recommended for plague that occurs following exposure to <i>Y. pestis</i> in the context of biologic warfare or bioterrorism.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;683&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;688&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Postexposure prophylaxis following high-risk exposure to <i>Y. pestis</i> (e.g., household, hospital, or other close contact with an individual who has pneumonic plague; laboratory exposure to viable <i>Y. pestis</i>; confirmed exposure in the context of biologic warfare or bioterrorism).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;683&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;688&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Drugs of choice for such prophylaxis are doxycycline (or tetracycline) or a fluoroquinolone (ciprofloxacin, levofloxacin, moxifloxacin, ofloxacin).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;683&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;688&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="dosage">Moxifloxacin (Systemic) Dosage and Administration</h2><h3>Administration</h3><p>Administer orally or by slow IV infusion.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Do <i>not</i> give IM, sub-Q, intrathecally, or intraperitoneally.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>IV route indicated in patients who do not tolerate or are unable to take the drug orally and in other patients when IV route offers a clinical advantage.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; If IV route used initially, switch to oral route when clinically indicated.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Patients receiving oral or IV moxifloxacin should be well hydrated and instructed to drink fluids liberally.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Administer tablets orally without regard to meals.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Pharmacokinetics.)</p><p>Administer orally at least 4 hours before or 8 hours after antacids containing magnesium or aluminum, metal cations (e.g., iron), sucralfate, multivitamins or dietary supplements containing iron or zinc, or buffered didanosine (pediatric oral solution admixed with antacid).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Interactions.)</p><p>Premixed injection for IV infusion containing 400 mg of moxifloxacin in 0.8% sodium chloride injection in single-use flexible container may be used without further dilution.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Do not admix with other drugs or infuse simultaneously through same tubing with other drugs.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; If same IV line or a Y-type line used for sequential infusion of other drugs or if piggyback method of administration used, flush tubing before and after infusion of moxifloxacin using IV solution compatible with both moxifloxacin and the other drug(s).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Inspect visually for particulate matter prior to administration;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; the premixed solution should appear yellow.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Does not contain preservatives; discard any unused portions.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>For solution and drug compatibility information, see Compatibility under Stability.</p><p>Administer by IV infusion over 1 hour.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Avoid rapid IV infusion.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Dosage</h3><p>Available as moxifloxacin hydrochloride;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; dosage expressed in terms of moxifloxacin.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Dosage of oral and IV moxifloxacin is identical.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Dosage adjustments not needed when switching from IV to oral administration.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Preterm neonates† (gestational age 32–37 weeks) ≤4 weeks of age: 5 mg/kg once daily.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;671&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Full-term neonates† ≤4 weeks of age: 10 mg/kg once daily.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;671&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Infants 3 months to &lt;2 years of age†: 6 mg/kg (up to 200 mg) every 12 hours.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;671&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Children 2–5 years of age†: 5 mg/kg (up to 200 mg) every 12 hours.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;671&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Children 6–11 years of age†: 4 mg/kg (up to 200 mg) every 12 hours.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;671&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Adolescents 12–17 years of age†: 4 mg/kg (up to 200 mg) every 12 hours in those weighing &lt;45 kg and 400 mg once daily in those weighing ≥45 kg.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;671&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Used in multiple-drug parenteral regimen for initial treatment of systemic anthrax (inhalational, GI, meningitis, or cutaneous anthrax with systemic involvement, lesions on the head or neck, or extensive edema).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;671&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Continue parenteral regimen for ≥2–3 weeks until patient is clinically stable and can be switched to appropriate oral anti-infective.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;671&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>If systemic anthrax occurred after exposure to aerosolized <i>B. anthracis</i> spores in the context of biologic warfare or bioterrorism, continue oral follow-up regimen until 60 days after illness onset.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;671&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>400 mg once daily for 10 days.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Respiratory Tract Infections under Uses.)</p><p>400 mg once daily for 5 days.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Respiratory Tract Infections under Uses.)</p><p>400 mg once daily for 7–14 days.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>400 mg once daily for 7 days.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>400 mg once daily for 7–21 days.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Initiate therapy with 400 mg IV once daily.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;708&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; When appropriate, switch to oral moxifloxacin 400 mg once daily.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Manufacturer recommends total treatment duration of 5–14 days.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; IDSA recommends treatment duration of 4–7 days;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;708&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; longer duration not associated with improved outcome and not recommended unless adequate source control is difficult to achieve.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;708&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>HIV-infected: 400 mg once daily.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;440&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Recommended treatment duration is 7–10 days for gastroenteritis or ≥14 days for bacteremic infections.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;440&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Duration of 2–6 weeks recommended for recurrent infections.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;440&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>HIV-infected: 400 mg once daily.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;440&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Recommended treatment duration is 7–14 days if CD4<sup>+</sup> T-cells ≥200 cells/mm<sup>3</sup> (≥14 days if bacteremic or infection is complicated) or 2–6 weeks if CD4<sup>+</sup> T-cells &lt;200 cells/mm<sup>3</sup>.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;440&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Consider secondary prophylaxis in those with recurrent bacteremia;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;440&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; also may also consider in those with recurrent gastroenteritis (with or without bacteremia) or with CD4<sup>+</sup> T-cells &lt;200 cells/mm<sup>3</sup> and severe diarrhea.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;440&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Discontinue secondary prophylaxis if <i>Salmonella</i> infection resolves and there has been a sustained response to antiretroviral therapy with CD4<sup>+</sup> T-cells &gt;200 cells/mm<sup>3</sup>.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;440&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>HIV-infected: 400 mg once daily.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;440&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Recommended treatment duration is 7–10 days for gastroenteritis or ≥14 days for bacteremic infections.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;440&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Up to 6 weeks may be required for recurrent infections, especially if CD4<sup>+</sup> T-cells &lt;200 cells/mm<sup>3</sup>.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;440&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>400 mg once daily.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;672&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;673&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Initiate prophylaxis as soon as possible following suspected or confirmed exposure to aerosolized <i>B. anthracis</i> spores.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;668&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;673&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;683&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Because of possible persistence of <i>B. anthracis</i> spores in lung tissue following an aerosol exposure, CDC and others recommend that anti-infective postexposure prophylaxis be continued for 60 days following a confirmed exposure.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;668&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;672&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;673&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;683&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>400 mg once daily.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;672&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;673&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Recommended duration is 60 days if cutaneous anthrax occurred after exposure to aerosolized <i>B. anthracis</i> spores in the context of biologic warfare or bioterrorism.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;668&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;672&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;673&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;683&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;686&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>400 mg once daily.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;668&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;672&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;673&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Used in multiple-drug parenteral regimen for initial treatment of systemic anthrax (inhalational, GI, meningitis, or cutaneous anthrax with systemic involvement, lesions on the head or neck, or extensive edema).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;672&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;673&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Continue parenteral regimen for ≥2–3 weeks until patient is clinically stable and can be switched to appropriate oral anti-infective.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;672&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;673&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>If anthrax occurred after exposure to aerosolized <i>B. anthracis</i> spores in the context of biologic warfare or bioterrorism, continue oral follow-up regimen until 60 days after illness onset.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;672&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;673&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>400 mg once daily.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;218&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Must be used in conjunction with other antituberculosis agents.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;218&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>ATS, CDC, and IDSA state data insufficient to date to support intermittent moxifloxacin regimens for treatment of tuberculosis.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;218&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>HIV-infected: 400 mg once daily.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;440&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>400 mg once daily for 7 days recommended by CDC for persistent or recurrent NGU in those initially treated with azithromycin.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;344&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Uses: Nongonococcal Urethritis.)</p><p>400 mg once daily for 10–14 days.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Initiate as soon as possible after suspected or known exposure to <i>Y. pestis</i>.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Prescribing Limits</h3><p>Do not exceed usual dosage or duration of therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Special Populations</h3><p>Adults with mild, moderate, or severe hepatic impairment (Child-Pugh class A, B, or C): Dosage adjustments not necessary.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Use with caution.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Hepatic Impairment under Cautions.)</p><p>Adults with renal impairment, including those on hemodialysis or CAPD: Dosage adjustments not necessary.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Dosage adjustment based solely on age not necessary.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="cautions">Cautions for Moxifloxacin (Systemic)</h2><h3>Contraindications</h3><ul>
<li>
<p>History of hypersensitivity to moxifloxacin or other quinolones.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
</ul><p>History of hypersensitivity to moxifloxacin or other quinolones.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Warnings/Precautions</h3><p>Systemic fluoroquinolones, including moxifloxacin, associated with disabling and potentially irreversible serious adverse reactions (e.g., tendinitis and tendon rupture, peripheral neuropathy, CNS effects) that can occur together in the same patient.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;140&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;145&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; May occur within hours to weeks after a systemic fluoroquinolone is initiated;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; have occurred in all age groups and in patients without preexisting risk factors for such adverse reactions.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Immediately discontinue moxifloxacin at first signs or symptoms of any serious adverse reactions.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;140&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;145&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Avoid systemic fluoroquinolones, including moxifloxacin, in patients who have experienced any of the serious adverse reactions associated with fluoroquinolones.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;140&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;145&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Systemic fluoroquinolones, including moxifloxacin, are associated with an increased risk of tendinitis and tendon rupture in all age groups.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;128&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;129&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Risk of developing fluoroquinolone-associated tendinitis and tendon rupture increased in older adults (usually those &gt;60 years of age), individuals receiving concomitant corticosteroids, and kidney, heart, or lung transplant recipients.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;128&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;129&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Geriatric Use under Cautions.)</p><p>Other factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Tendinitis and tendon rupture have been reported in patients receiving fluoroquinolones who did not have any risk factors for such adverse reactions.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Fluoroquinolone-associated tendinitis and tendon rupture most frequently involve the Achilles tendon;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; also reported in the rotator cuff (shoulder), hand, biceps, thumb, and other tendon sites.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Tendinitis and tendon rupture can occur within hours or days after moxifloxacin is initiated or as long as several months after completion of therapy and can occur bilaterally.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Immediately discontinue moxifloxacin if pain, swelling, inflammation, or rupture of a tendon occurs.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;128&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;129&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Advice to Patients.)</p><p>Avoid systemic fluoroquinolones, including moxifloxacin, in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Systemic fluoroquinolones, including moxifloxacin, are associated with an increased risk of peripheral neuropathy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Sensory or sensorimotor axonal polyneuropathy affecting small and/or large axons resulting in paresthesias, hypoesthesias, dysesthesias, and weakness reported with fluoroquinolones, including moxifloxacin.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;130&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Symptoms may occur soon after initiation of the drug and, in some patients, may be irreversible.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;130&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Immediately discontinue moxifloxacin if symptoms of peripheral neuropathy (e.g., pain, burning, tingling, numbness, and/or weakness) occur or if there are other alterations in sensations (e.g., light touch, pain, temperature, position sense, vibratory sensation).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;130&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Avoid systemic fluoroquinolones, including moxifloxacin, in patients who have experienced peripheral neuropathy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Systemic fluoroquinolones, including moxifloxacin, are associated with increased risk of psychiatric adverse effects, including toxic psychosis,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; hallucinations,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; paranoia,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; depression,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; suicidal thoughts or acts,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; agitation,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;171&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; nervousness,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;171&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; confusion,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; delirium,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;171&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; disorientation,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;171&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; disturbances in attention,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;171&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; insomnia,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; nightmares,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; and memory impairment.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;171&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; These adverse effects may occur after first dose.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Systemic fluoroquinolones, including moxifloxacin, are associated with increased risk of seizures (convulsions), increased intracranial pressure (including pseudotumor cerebri), dizziness, and tremors.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; These CNS effects may occur after first dose.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Use with caution in patients with known or suspected CNS disorders (e.g., severe cerebral arteriosclerosis, epilepsy) or other risk factors that predispose to seizures or lower seizure threshold.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>If psychiatric or other CNS effects occur, immediately discontinue moxifloxacin and institute appropriate measures.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Advice to Patients.)</p><p>Fluoroquinolones, including moxifloxacin, have neuromuscular blocking activity and may exacerbate muscle weakness in myasthenia gravis patients;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; death or need for ventilatory support reported.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Avoid use in patients with known history of myasthenia gravis.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Advice to Patients.)</p><p>Serious and occasionally fatal hypersensitivity and/or anaphylactic reactions reported in patients receiving fluoroquinolones, including moxifloxacin.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Although generally reported after multiple doses, these reactions may occur with first dose.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Some hypersensitivity reactions have been accompanied by cardiovascular collapse, loss of consciousness, tingling, edema (pharyngeal or facial), dyspnea, urticaria, or pruritus.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Other serious and sometimes fatal adverse reactions reported with fluoroquinolones, including moxifloxacin, that may or may not be related to hypersensitivity reactions include one or more of the following: fever, rash or other severe dermatologic reactions (e.g., toxic epidermal necrolysis, Stevens-Johnson syndrome); vasculitis, arthralgia, myalgia, serum sickness; allergic pneumonitis; interstitial nephritis, acute renal insufficiency or failure; hepatitis, jaundice, acute hepatic necrosis or failure; anemia (including hemolytic and aplastic), thrombocytopenia (including thrombotic thrombocytopenic purpura), leukopenia, agranulocytosis, pancytopenia, and/or other hematologic effects.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Immediately discontinue moxifloxacin at first appearance of rash, jaundice, or any other sign of hypersensitivity.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;23&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Institute appropriate therapy as indicated (e.g., epinephrine, corticosteroids, maintenance of an adequate airway and oxygen).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Moderate to severe photosensitivity/phototoxicity reactions reported with fluoroquinolones, including moxifloxacin.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Phototoxicity may manifest as exaggerated sunburn reactions (e.g., burning, erythema, exudation, vesicles, blistering, edema) on areas exposed to sun or artificial ultraviolet (UV) light (usually the face, neck, extensor surfaces of forearms, dorsa of hands).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Avoid unnecessary or excessive exposure to sunlight or artificial UV light (tanning beds, UVA/UVB treatment) while receiving moxifloxacin.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; If patient needs to be outdoors, they should wear loose-fitting clothing that protects skin from sun exposure and use other sun protection measures (sunscreen).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Discontinue moxifloxacin if photosensitivity or phototoxicity (sunburn-like reaction, skin eruption) occurs.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Prolonged QT interval leading to ventricular arrhythmias, including torsades de pointes, reported with some fluoroquinolones, including moxifloxacin.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;55&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Do not exceed usual recommended dosage or IV infusion rate since this may increase risk of prolonged QT interval.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Avoid use in patients with known prolonged QT interval, ventricular arrhythmias (including torsades de pointes), any ongoing proarrhythmic conditions (including clinically important bradycardia and acute myocardial ischemia), or uncorrected hypokalemia or hypomagnesemia.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Avoid use in patients receiving class IA (e.g., quinidine, procainamide) or class III (e.g., amiodarone, sotalol) antiarrhythmic agents or other drugs that prolong QT interval (e.g., cisapride [available in the US only under a limited-access protocol], erythromycin, antipsychotic agents, tricyclic antidepressants).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Drugs that Prolong QT Interval under Interactions.)</p><p>Risk of QT interval prolongation may be increased in geriatric patients.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Geriatric Use under Cautions.)</p><p>Use with caution in patients with mild, moderate, or severe liver cirrhosis.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Hepatic Impairment under Cautions.)</p><p>Rupture or dissection of aortic aneurysms reported in patients receiving systemic fluoroquinolones.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;172&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Epidemiologic studies indicate an increased risk of aortic aneurysm and dissection within 2 months following use of systemic fluoroquinolones, particularly in geriatric patients.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Cause for this increased risk not identified.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;172&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Unless there are no other treatment options, do not use systemic fluoroquinolones, including moxifloxacin, in patients who have an aortic aneurysm or are at increased risk for an aortic aneurysm.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;172&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; This includes geriatric patients and patients with peripheral atherosclerotic vascular disease, hypertension, or certain genetic conditions (e.g., Marfan syndrome, Ehlers-Danlos syndrome).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;172&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>If patient reports adverse effects suggestive of aortic aneurysm or dissection, immediately discontinue the fluoroquinolone.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;172&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Advice to Patients.)</p><p>Systemic fluoroquinolones, including moxifloxacin, are associated with alterations in blood glucose concentrations, including symptomatic hypoglycemia and hyperglycemia.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;171&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Blood glucose disturbances during fluoroquinolone therapy usually have occurred in patients with diabetes mellitus receiving an oral antidiabetic agent (e.g., glyburide) or insulin.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;171&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Severe cases of hypoglycemia resulting in coma or death reported with some systemic fluoroquinolones.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;171&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Although most reported cases of hypoglycemic coma involved patients with risk factors for hypoglycemia (e.g., older age, diabetes mellitus, renal insufficiency, concomitant use of antidiabetic agents [especially sulfonylureas]), some involved patients receiving a fluoroquinolone who were not diabetic and not receiving an oral antidiabetic agent or insulin.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;171&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Carefully monitor blood glucose concentrations when moxifloxacin used in diabetic patients receiving antidiabetic agents.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;171&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>If a hypoglycemic reaction occurs, discontinue the fluoroquinolone and initiate appropriate therapy immediately.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Advice to Patients.)</p><p>Fluoroquinolones, including moxifloxacin, cause arthropathy and osteochondrosis in immature animals of various species.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;88&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;89&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;90&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;91&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;92&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;93&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;94&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;95&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Permanent lesions in cartilage reported in moxifloxacin studies in immature dogs.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Safety and efficacy not established in children and adolescents &lt;18 years of age (see Pediatric Use under Cautions) or in pregnant or lactating women (see Pregnancy and see Lactation under Cautions).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Treatment with anti-infectives alters normal colon flora and may permit overgrowth of <i>Clostridioides difficile</i> (formerly known as <i>Clostridium difficile</i>).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;302&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;303&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;304&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; <i>C. difficile</i> infection (CDI) and <i>C. difficile</i>-associated diarrhea and colitis (CDAD; also known as antibiotic-associated diarrhea and colitis or pseudomembranous colitis) reported with nearly all anti-infectives, including moxifloxacin, and may range in severity from mild diarrhea to fatal colitis.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;76&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;80&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;81&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;302&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;303&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;304&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; <i>C. difficile</i> produces toxins A and B which contribute to development of CDAD;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;302&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; hypertoxin-producing strains of <i>C. difficile</i> are associated with increased morbidity and mortality since they may be refractory to anti-infectives and colectomy may be required.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Consider CDAD if diarrhea develops and manage accordingly.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;302&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;303&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;304&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Careful medical history necessary since CDAD may occur as late as 2 months or longer after anti-infective therapy is discontinued.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>If CDAD suspected or confirmed, discontinue anti-infectives not directed against <i>C. difficile</i> as soon as possible.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;302&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Initiate appropriate anti-infective therapy directed against <i>C. difficile</i> (e.g., vancomycin, fidaxomicin, metronidazole), supportive therapy (e.g., fluid and electrolyte management, protein supplementation), and surgical evaluation as clinically indicated.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;302&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;303&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;304&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Use for treatment of acute bacterial sinusitis or acute bacterial exacerbations of chronic bronchitis <i>only</i> when no other treatment options available.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;140&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;145&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Because moxifloxacin, like other systemic fluoroquinolones, has been associated with disabling and potentially irreversible serious adverse reactions (e.g., tendinitis and tendon rupture, peripheral neuropathy, CNS effects) that can occur together in the same patient, risks of serious adverse reactions outweigh benefits for patients with these infections.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;140&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;145&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>To reduce development of drug-resistant bacteria and maintain effectiveness of moxifloxacin and other antibacterials, use only for treatment or prevention of infections proven or strongly suspected to be caused by susceptible bacteria.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>When selecting or modifying anti-infective therapy, use results of culture and in vitro susceptibility testing.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; In the absence of such data, consider local epidemiology and susceptibility patterns when selecting anti-infectives for empiric therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Information on test methods and quality control standards for in vitro susceptibility testing of antibacterial agents and specific interpretive criteria for such testing recognized by FDA is available at [Web].&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Human data for moxifloxacin insufficient to inform any drug-associated risk regarding use during pregnancy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Based on animal studies, moxifloxacin may cause fetal harm.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Not teratogenic in pregnant rats, rabbits, and monkeys at exposures up to 2.5 times higher than human exposures reported with usual dosage, but embryofetal toxicity (e.g., decreased neonatal body weights, increased incidence of skeletal variations [rib and vertebra combined], increased fetal loss) observed in pregnant rats or rabbits at dosages associated with maternal toxicity.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Advise pregnant women of potential risk to fetus.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Not known whether distributed into human milk;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; distributed into milk in rats.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Consider developmental and health benefits of breast-feeding along with the mother's clinical need for moxifloxacin;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; also consider potential adverse effects on breast-fed infant from the drug or underlying maternal condition.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Efficacy not established for any indication in children or adolescents &lt;18 years of age.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Limited data available from a clinical study in pediatric patients ≥3 months of age indicate overall safety profile of the drug in pediatric patients is comparable to that reported in adults.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Like other fluoroquinolones, moxifloxacin causes arthropathy in juvenile animals.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Musculoskeletal Effects under Cautions.)</p><p>AAP states use of a systemic fluoroquinolone may be justified in children &lt;18 years of age in certain specific circumstances when there are no safe and effective alternatives and the drug is known to be effective.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;110&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;292&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>No overall differences in safety or efficacy relative to younger adults.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Risk of severe tendon disorders, including tendon rupture, is increased in older adults (usually those &gt;60 years of age).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;128&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;129&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; This risk is further increased in those receiving concomitant corticosteroids.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;128&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;129&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Tendinitis and Tendon Rupture under Cautions.) Use caution in geriatric adults, especially those receiving concomitant corticosteroids.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Risk of QT interval prolongation may be increased in geriatric patients.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Prolongation of QT Interval under Cautions.)</p><p>Risk of aortic aneurysm and dissection may be increased in geriatric patients.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Risk of Aortic Aneurysm and Dissection under Cautions.)</p><p>Dosage adjustments not necessary in adults with mild, moderate, or severe hepatic impairment (Child-Pugh class A, B, or C).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Use with caution in patients with any degree of hepatic impairment;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; monitor ECGs in those with liver cirrhosis.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Metabolic disturbances associated with hepatic insufficiency may lead to QT interval prolongation.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Dosage adjustments not necessary in adults with renal impairment.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Common Adverse Effects</h3><p>GI effects (nausea, diarrhea), headache, dizziness.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="interactions">Interactions for Moxifloxacin (Systemic)</h2><p>Not metabolized by CYP isoenzymes and does not inhibit CYP3A4, 2D6, 2C9, 2C19, or 1A2.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Pharmacokinetic interactions with drugs metabolized by CYP isoenzymes unlikely.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Drugs That Prolong QT Interval</h3><p>Potential pharmacologic interaction (additive effect on QT interval prolongation).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Avoid use in patients receiving class IA (e.g., quinidine, procainamide) or class III (e.g., amiodarone, sotalol) antiarrhythmic agents.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Use with caution in patients receiving drugs that prolong QT interval (e.g., cisapride [commercially available under a limited-access protocol only], erythromycin, antipsychotic agents, tricyclic antidepressants).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Prolongation of QT Interval under Cautions.)</p><h3>Specific Drugs</h3><p>Drug</p><p>Interaction</p><p>Comments</p><p>Antacids (aluminum- or magnesium-containing)</p><p>Decreased absorption of oral moxifloxacin&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Administer oral moxifloxacin at least 4 hours before or 8 hours after such antacids&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Anticoagulants, oral (warfarin)</p><p>No clinically important pharmacokinetic interactions;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; may enhance anticoagulant effects of warfarin&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Monitor PT, INR, or other suitable coagulation tests&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Antidiabetic agents (sulfonylureas, insulin)</p><p>Alterations in blood glucose concentrations (hypoglycemia and hyperglycemia) reported&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Glyburide: No clinically important effect on glyburide pharmacokinetics&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Closely monitor blood glucose concentrations;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; if hypoglycemic reaction occurs, immediately discontinue moxifloxacin and initiate appropriate therapy&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Antifungal agents, azoles</p><p>Itraconazole: No effect on pharmacokinetics of either drug&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Atenolol</p><p>No effect on atenolol pharmacokinetics&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Calcium supplements</p><p>No effect on moxifloxacin pharmacokinetics&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Corticosteroids</p><p>Increased risk of tendinitis or tendon rupture, especially in patients &gt;60 years of age&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Cyclosporine</p><p>No clinically important effect on pharmacokinetics of either drug&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Didanosine</p><p>Decreased absorption of oral moxifloxacin with buffered didanosine preparations&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Administer oral moxifloxacin at least 4 hours before or 8 hours after buffered didanosine (pediatric oral solution admixed with antacid)&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Digoxin</p><p>Transient increase in digoxin concentrations; no clinically important effect on pharmacokinetics of either drug&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Dosage adjustment not needed for either drug&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Estrogens/progestins</p><p>No clinically important effect on pharmacokinetics of ethinyl estradiol/levonorgestrel oral contraceptives&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Iron preparations</p><p>Decreased oral absorption of moxifloxacin&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;82&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Administer oral moxifloxacin at least 4 hours before or 8 hours after iron preparations&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Morphine</p><p>No clinically important effect on moxifloxacin pharmacokinetics&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Multivitamins and dietary supplements</p><p>Decreased oral absorption of moxifloxacin&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Administer oral moxifloxacin at least 4 hours before or 8 hours after multivitamins or dietary supplements containing iron or zinc&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>NSAIAs</p><p>Possible increased risk of CNS stimulation, seizures;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; animal studies using other fluoroquinolones suggest risk varies depending on the specific NSAIA&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;86&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Probenecid</p><p>No clinically important effect on moxifloxacin pharmacokinetics&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Ranitidine</p><p>No clinically important effect on moxifloxacin pharmacokinetics&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Sucralfate</p><p>Decreased oral absorption of moxifloxacin&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Administer oral moxifloxacin at least 4 hours before or 8 hours after sucralfate&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Theophylline</p><p>No clinically important effect on pharmacokinetics of either drug&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="pharmacokinetics">Moxifloxacin (Systemic) Pharmacokinetics</h2><h3>Absorption</h3><p>86–92%.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Peak plasma concentrations attained within 0.5–4 hours; steady-state attained after at least 3 days.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Administration of a 400-mg tablet with a high-fat breakfast or with yogurt does not have a clinically important effect on absorption of the drug.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;83&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;84&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Distribution</h3><p>Widely distributed into body tissues and fluids, including saliva, nasal and bronchial secretions, sinus mucosa, skin blister fluid, subcutaneous tissue, skeletal muscle, and abdominal tissues and fluids.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Distributed into CSF in rabbits.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;48&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Distributed into milk in rats; may be distributed into human milk.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>30–50%.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Elimination</h3><p>Approximately 52% of an oral or IV dose is metabolized via glucuronide and sulfate conjugation; the metabolites are not microbiologically active.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Not metabolized by CYP isoenzymes.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Eliminated in urine and by biliary excretion and metabolism.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;33&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Approximately 45% of an oral or IV dose excreted unchanged (20% in urine and 25% in feces).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; A total of 96% of an oral dose is excreted as unchanged drug or metabolites.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Adults with normal renal and hepatic function: Mean of 11.5–15.6 hours following single or multiple oral doses.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;33&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;34&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Adults with normal renal and hepatic function: Mean of 8.2–15.4 hours following single or multiple IV doses.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Pharmacokinetics in geriatric patients similar to younger adults.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Concentrations of sulfate and glucuronide conjugates are increased in patients with mild or moderate hepatic impairment (Child-Pugh class A or B); clinical importance not determined.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Plasma concentrations of moxifloxacin and its metabolites in patients with severe hepatic impairment (Child-Pugh class C) are similar to those reported in patients with mild or moderate hepatic impairment.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Pharmacokinetics not substantially affected by mild, moderate, or severe renal impairment.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; In patients with Cl<sub>cr</sub> &lt;20 mL/minute undergoing hemodialysis or CAPD, moxifloxacin concentrations are not affected but concentrations of the sulfate and glucuronide conjugates are increased; clinical importance of this has not be determined.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2>Stability</h2><h3>Storage</h3><p>25°C (may be exposed to 15–30°C).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Avoid high humidity.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>25°C (may be exposed to 15–30°C).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Do not refrigerate.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>For single-use only, discard any unused portions.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Compatibility</h3><p>For information on systemic interactions resulting from concomitant use, see Interactions.</p><p>Compatible</p><p>Dextrose 5 or 10% in water</p><p>Ringer’s injection, lactated</p><p>Sodium chloride 0.9%</p><p>Compatible</p><p>Cangrelor tetrasodium</p><p>Ceftaroline fosamil</p><p>Doripenem</p><p>Hydroxyethyl starch 130/0.4 in sodium chloride 0.9%</p><p>Vasopressin</p><h2>Actions and Spectrum</h2><ul>
<li>
<p>Usually bactericidal.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Like other fluoroquinolones, moxifloxacin inhibits bacterial DNA gyrase and topoisomerase IV.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Spectrum of activity includes gram-positive aerobic bacteria, some gram-negative aerobic bacteria, some anaerobic bacteria, and some other organisms (e.g., <i>Chlamydia</i>, <i>Mycoplasma</i>, <i>Mycobacterium</i>).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;23&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;24&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;28&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>More active in vitro than some other fluoroquinolones (e.g., ciprofloxacin, levofloxacin, ofloxacin) against <i>S. pneumoniae</i>&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;7&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;8&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;9&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; while generally retaining the in vitro activity of these drugs against gram-negative bacteria and etiologic agents of atypical pneumonia (e.g., <i>C. pneumoniae</i>, <i>M. pneumoniae</i>, <i>Legionella</i>).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;7&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;8&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Gram-positive aerobes: Active in vitro and in clinical infections against <i>Enterococcus faecalis</i>, <i>Staphylococcus aureus</i> (methicillin-susceptible [oxacillin-susceptible] strains only),&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;24&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; <i>S. pneumoniae</i> (including multidrug-resistant strains),&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;56&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; <i>S. anginosus</i>,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; <i>S. constellatus</i>,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;24&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;27&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; and <i>S. pyogenes</i> (group A β-hemolytic streptococci).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;24&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Also active in vitro against <i>S. epidermidis</i> (oxacillin-susceptible strains only),&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;24&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; <i>S. agalactiae</i> (group B streptococci),&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;24&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; and viridans streptococci.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Gram-negative aerobes: Active in vitro and in clinical infections against <i>Enterobacter cloacae</i>,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; <i>Escherichia coli</i>,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;24&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; H. influenzae,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;24&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; <i>H. parainfluenzae</i>,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; <i>K. pneumoniae</i>,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; <i>M. catarrhalis</i>,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; and <i>Proteus mirabilis</i>.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Active against <i>Y. pestis</i> in vitro and in a primate infection model.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Also active in vitro against <i>Citrobacter freundii</i>,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;24&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; <i>K. oxytoca</i>,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; <i>and Legionella pneumophila</i>.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Anaerobes and other organisms: Active in vitro and in clinical infections against <i>Bacteroides fragilis</i>, <i>B. thetaiotaomicron</i>, <i>Clostridium perfringens</i>, <i>C. pneumoniae</i>, <i>Peptostreptococcus</i>,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;24&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;41&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; and <i>M. pneumoniae</i>.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Also active in vitro against <i>M. tuberculosis</i>,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;23&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;24&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;28&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; <i>M. avium complex</i> (MAC), &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;23&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; <i>M. kansasii</i>,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;23&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; <i>M. fortuitum</i>,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;23&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;29&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; <i>Fusobacterium</i>,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; and <i>Prevotella</i>.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;24&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Active against some strains of <i>M. tuberculosis</i> resistant to isoniazid, rifampin, or streptomycin,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;24&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;28&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; but moxifloxacin-resistant <i>M. tuberculosis</i> have been reported and some multidrug-resistant strains (i.e., strains resistant to rifampin and isoniazid) also are resistant to moxifloxacin or other fluoroquinolones.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;64&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;66&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;67&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;68&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;69&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;71&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;72&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Resistance to fluoroquinolones can occur as the result of mutations in topoisomerase II (DNA gyrase) or topoisomerase IV genes, decreased outer membrane permeability, or drug efflux.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; In vitro, resistance to moxifloxacin develops slowly by multiple-step mutations.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Some cross-resistance occurs between moxifloxacin and other fluoroquinolones.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
</ul><p>Usually bactericidal.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Like other fluoroquinolones, moxifloxacin inhibits bacterial DNA gyrase and topoisomerase IV.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Spectrum of activity includes gram-positive aerobic bacteria, some gram-negative aerobic bacteria, some anaerobic bacteria, and some other organisms (e.g., <i>Chlamydia</i>, <i>Mycoplasma</i>, <i>Mycobacterium</i>).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;23&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;24&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;28&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>More active in vitro than some other fluoroquinolones (e.g., ciprofloxacin, levofloxacin, ofloxacin) against <i>S. pneumoniae</i>&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;7&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;8&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;9&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; while generally retaining the in vitro activity of these drugs against gram-negative bacteria and etiologic agents of atypical pneumonia (e.g., <i>C. pneumoniae</i>, <i>M. pneumoniae</i>, <i>Legionella</i>).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;7&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;8&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Gram-positive aerobes: Active in vitro and in clinical infections against <i>Enterococcus faecalis</i>, <i>Staphylococcus aureus</i> (methicillin-susceptible [oxacillin-susceptible] strains only),&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;24&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; <i>S. pneumoniae</i> (including multidrug-resistant strains),&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;56&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; <i>S. anginosus</i>,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; <i>S. constellatus</i>,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;24&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;27&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; and <i>S. pyogenes</i> (group A β-hemolytic streptococci).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;24&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Also active in vitro against <i>S. epidermidis</i> (oxacillin-susceptible strains only),&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;24&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; <i>S. agalactiae</i> (group B streptococci),&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;24&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; and viridans streptococci.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Gram-negative aerobes: Active in vitro and in clinical infections against <i>Enterobacter cloacae</i>,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; <i>Escherichia coli</i>,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;24&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; H. influenzae,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;24&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; <i>H. parainfluenzae</i>,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; <i>K. pneumoniae</i>,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; <i>M. catarrhalis</i>,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; and <i>Proteus mirabilis</i>.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Active against <i>Y. pestis</i> in vitro and in a primate infection model.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Also active in vitro against <i>Citrobacter freundii</i>,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;24&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; <i>K. oxytoca</i>,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; <i>and Legionella pneumophila</i>.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Anaerobes and other organisms: Active in vitro and in clinical infections against <i>Bacteroides fragilis</i>, <i>B. thetaiotaomicron</i>, <i>Clostridium perfringens</i>, <i>C. pneumoniae</i>, <i>Peptostreptococcus</i>,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;24&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;41&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; and <i>M. pneumoniae</i>.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Also active in vitro against <i>M. tuberculosis</i>,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;23&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;24&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;28&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; <i>M. avium complex</i> (MAC), &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;23&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; <i>M. kansasii</i>,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;23&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; <i>M. fortuitum</i>,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;23&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;29&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; <i>Fusobacterium</i>,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; and <i>Prevotella</i>.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;24&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Active against some strains of <i>M. tuberculosis</i> resistant to isoniazid, rifampin, or streptomycin,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;24&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;28&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; but moxifloxacin-resistant <i>M. tuberculosis</i> have been reported and some multidrug-resistant strains (i.e., strains resistant to rifampin and isoniazid) also are resistant to moxifloxacin or other fluoroquinolones.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;64&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;66&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;67&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;68&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;69&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;71&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;72&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Resistance to fluoroquinolones can occur as the result of mutations in topoisomerase II (DNA gyrase) or topoisomerase IV genes, decreased outer membrane permeability, or drug efflux.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; In vitro, resistance to moxifloxacin develops slowly by multiple-step mutations.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Some cross-resistance occurs between moxifloxacin and other fluoroquinolones.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="patient-advice">Advice to Patients</h2><ul>
<li>
<p>Advise patients to read manufacturer’s patient information (medication guide) prior to initiating moxifloxacin therapy and each time prescription refilled.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Advise patients that antibacterials (including moxifloxacin) should only be used to treat bacterial infections and not used to treat viral infections (e.g., the common cold).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of completing full course of therapy, even if feeling better after a few days.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Advise patients that skipping doses or not completing the full course of therapy may decrease effectiveness and increase the likelihood that bacteria will develop resistance and will not be treatable with moxifloxacin or other antibacterials in the future.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>May be taken without regard to meals,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; but should be taken with liberal amounts of fluids.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of taking moxifloxacin at least 4 hours before or 8 hours after multivitamins or dietary supplements containing iron or zinc; aluminum- or magnesium-containing antacids; or buffered didanosine (pediatric oral solution admixed with antacid).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Inform patients that systemic fluoroquinolones, including moxifloxacin, have been associated with disabling and potentially irreversible serious adverse reactions (e.g., tendinitis and tendon rupture, peripheral neuropathy, CNS effects) that may occur together in same patient.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;140&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;145&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Advise patients to immediately discontinue moxifloxacin and contact a clinician if they experience any signs or symptoms of serious adverse effects (e.g., unusual joint or tendon pain, muscle weakness, a “pins and needles” tingling or pricking sensation, numbness of the arms or legs, confusion, hallucinations) while taking the drug.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;140&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;145&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Advise patients to talk with a clinician if they have any questions or concerns.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;140&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;145&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Inform patients that systemic fluoroquinolones, including moxifloxacin, are associated with an increased risk of tendinitis and tendon rupture in all age groups and this risk is increased risk in adults &gt;60 years of age, individuals receiving corticosteroids, and kidney, heart, or lung transplant recipients.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Symptoms may be irreversible.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Importance of resting and refraining from exercise at the first sign of tendinitis or tendon rupture (e.g., pain, swelling, or inflammation of a tendon or weakness or inability to use a joint) and importance of immediately discontinuing the drug and contacting a clinician.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Tendinitis and Tendon Rupture under Cautions.)</p>
</li>
<li>
<p>Inform patients that peripheral neuropathies have been reported with systemic fluoroquinolones, including moxifloxacin, and that symptoms may occur soon after initiation of the drug and may be irreversible.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Importance of immediately discontinuing moxifloxacin and contacting a clinician if symptoms of peripheral neuropathy (e.g., pain, burning, tingling, numbness, and/or weakness) occur.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Inform patients that systemic fluoroquinolones, including moxifloxacin, have been associated with CNS effects (e.g., convulsions, dizziness, lightheadedness, increased intracranial pressure).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Importance of informing clinician of any history of epilepsy or seizures before initiating therapy with the drug.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Importance of contacting a clinician if persistent headache with or without blurred vision occurs.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Advise patients that moxifloxacin may cause dizziness and lightheadedness;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; caution patients not to engage in activities requiring mental alertness and motor coordination (e.g., driving a vehicle, operating machinery) until effects of the drug on the individual are known.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Advise patients that systemic fluoroquinolones, including moxifloxacin, may worsen myasthenia gravis symptoms;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; importance of informing clinician of any history of myasthenia gravis.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Importance of immediately contacting a clinician if any symptoms of muscle weakness, including respiratory difficulties, occur.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Inform patients that moxifloxacin may be associated with hypersensitivity reactions (including anaphylactic reactions), even after first dose.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Importance of immediately discontinuing moxifloxacin and contacting a clinician at first sign of rash, hives or other skin reaction, rapid heartbeat, difficulty swallowing or breathing, any swelling suggesting angioedema (e.g., swelling of lips, tongue, face; throat tightness; hoarseness), jaundice, or any other sign of hypersensitivity.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Inform patients that photosensitivity/phototoxicity reactions reported following exposure to sun or UV light in patients receiving fluoroquinolones.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Importance of avoiding or minimizing exposure to sunlight or artificial UV light (e.g., tanning beds, UVA/UVB treatment) and using protective measures (e.g., wearing loose-fitting clothes, sunscreen) if outdoors during moxifloxacin therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Importance of discontinuing moxifloxacin and contacting a clinician if a sunburn-like reaction or skin eruption occurs.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of informing clinician of personal or family history of QT interval prolongation or proarrhythmic conditions (e.g., hypokalemia, bradycardia, recent myocardial ischemia) and of concurrent therapy with any drugs that may affect QT interval (e.g., class IA [quinidine, procainamide] or class III [e.g., amiodarone, sotalol] antiarrhythmic agents).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Importance of contacting a clinician if symptoms of prolonged QT interval (e.g., prolonged heart palpitations, loss of consciousness) occur.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Inform patients that systemic fluoroquinolones may increase risk of aortic aneurysm and dissection;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;172&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; importance of informing clinician of any history of aneurysms, blockages or hardening of the arteries, high blood pressure, or genetic conditions such as Marfan syndrome or Ehlers-Danlos syndrome.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;172&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Advise patients to seek immediate medical treatment if they experience sudden, severe, and constant pain in the stomach, chest, or back.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;172&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Inform patients that hypoglycemia reported when systemic fluoroquinolones used in some patients receiving antidiabetic agents.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;171&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Advise patients with diabetes mellitus receiving oral antidiabetic agents or insulin to discontinue fluoroquinolone treatment and contact a clinician if they experience hypoglycemia or symptoms of hypoglycemia.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;171&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Inform patients that severe hepatotoxicity (including acute hepatitis and fatal events) reported in patients receiving moxifloxacin.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Importance of informing a clinician if any signs or symptoms of liver injury (e.g., loss of appetite, nausea, vomiting, fever, weakness, tiredness, right upper quadrant tenderness, itching, yellowing of the skin and eyes, light colored bowel movements, dark colored urine) occur.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Advise patients that diarrhea is a common problem caused by anti-infectives and usually ends when the drug is discontinued.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Importance of contacting a clinician if watery and bloody stools (with or without stomach cramps and fever) occur during or as late as 2 months or longer after the last dose.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of informing clinician of existing or contemplated concomitant therapy, including prescription and OTC drugs (e.g., drugs that may affect QT interval), as well as any concomitant illnesses.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of advising patients of other important precautionary information.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Cautions.)</p>
</li>
</ul><p>Advise patients to read manufacturer’s patient information (medication guide) prior to initiating moxifloxacin therapy and each time prescription refilled.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Advise patients that antibacterials (including moxifloxacin) should only be used to treat bacterial infections and not used to treat viral infections (e.g., the common cold).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of completing full course of therapy, even if feeling better after a few days.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Advise patients that skipping doses or not completing the full course of therapy may decrease effectiveness and increase the likelihood that bacteria will develop resistance and will not be treatable with moxifloxacin or other antibacterials in the future.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>May be taken without regard to meals,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; but should be taken with liberal amounts of fluids.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of taking moxifloxacin at least 4 hours before or 8 hours after multivitamins or dietary supplements containing iron or zinc; aluminum- or magnesium-containing antacids; or buffered didanosine (pediatric oral solution admixed with antacid).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Inform patients that systemic fluoroquinolones, including moxifloxacin, have been associated with disabling and potentially irreversible serious adverse reactions (e.g., tendinitis and tendon rupture, peripheral neuropathy, CNS effects) that may occur together in same patient.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;140&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;145&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Advise patients to immediately discontinue moxifloxacin and contact a clinician if they experience any signs or symptoms of serious adverse effects (e.g., unusual joint or tendon pain, muscle weakness, a “pins and needles” tingling or pricking sensation, numbness of the arms or legs, confusion, hallucinations) while taking the drug.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;140&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;145&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Advise patients to talk with a clinician if they have any questions or concerns.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;140&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;145&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Inform patients that systemic fluoroquinolones, including moxifloxacin, are associated with an increased risk of tendinitis and tendon rupture in all age groups and this risk is increased risk in adults &gt;60 years of age, individuals receiving corticosteroids, and kidney, heart, or lung transplant recipients.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Symptoms may be irreversible.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Importance of resting and refraining from exercise at the first sign of tendinitis or tendon rupture (e.g., pain, swelling, or inflammation of a tendon or weakness or inability to use a joint) and importance of immediately discontinuing the drug and contacting a clinician.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Tendinitis and Tendon Rupture under Cautions.)</p><p>Inform patients that peripheral neuropathies have been reported with systemic fluoroquinolones, including moxifloxacin, and that symptoms may occur soon after initiation of the drug and may be irreversible.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Importance of immediately discontinuing moxifloxacin and contacting a clinician if symptoms of peripheral neuropathy (e.g., pain, burning, tingling, numbness, and/or weakness) occur.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Inform patients that systemic fluoroquinolones, including moxifloxacin, have been associated with CNS effects (e.g., convulsions, dizziness, lightheadedness, increased intracranial pressure).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Importance of informing clinician of any history of epilepsy or seizures before initiating therapy with the drug.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Importance of contacting a clinician if persistent headache with or without blurred vision occurs.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Advise patients that moxifloxacin may cause dizziness and lightheadedness;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; caution patients not to engage in activities requiring mental alertness and motor coordination (e.g., driving a vehicle, operating machinery) until effects of the drug on the individual are known.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Advise patients that systemic fluoroquinolones, including moxifloxacin, may worsen myasthenia gravis symptoms;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; importance of informing clinician of any history of myasthenia gravis.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Importance of immediately contacting a clinician if any symptoms of muscle weakness, including respiratory difficulties, occur.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Inform patients that moxifloxacin may be associated with hypersensitivity reactions (including anaphylactic reactions), even after first dose.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Importance of immediately discontinuing moxifloxacin and contacting a clinician at first sign of rash, hives or other skin reaction, rapid heartbeat, difficulty swallowing or breathing, any swelling suggesting angioedema (e.g., swelling of lips, tongue, face; throat tightness; hoarseness), jaundice, or any other sign of hypersensitivity.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Inform patients that photosensitivity/phototoxicity reactions reported following exposure to sun or UV light in patients receiving fluoroquinolones.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Importance of avoiding or minimizing exposure to sunlight or artificial UV light (e.g., tanning beds, UVA/UVB treatment) and using protective measures (e.g., wearing loose-fitting clothes, sunscreen) if outdoors during moxifloxacin therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Importance of discontinuing moxifloxacin and contacting a clinician if a sunburn-like reaction or skin eruption occurs.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of informing clinician of personal or family history of QT interval prolongation or proarrhythmic conditions (e.g., hypokalemia, bradycardia, recent myocardial ischemia) and of concurrent therapy with any drugs that may affect QT interval (e.g., class IA [quinidine, procainamide] or class III [e.g., amiodarone, sotalol] antiarrhythmic agents).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Importance of contacting a clinician if symptoms of prolonged QT interval (e.g., prolonged heart palpitations, loss of consciousness) occur.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Inform patients that systemic fluoroquinolones may increase risk of aortic aneurysm and dissection;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;172&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; importance of informing clinician of any history of aneurysms, blockages or hardening of the arteries, high blood pressure, or genetic conditions such as Marfan syndrome or Ehlers-Danlos syndrome.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;172&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Advise patients to seek immediate medical treatment if they experience sudden, severe, and constant pain in the stomach, chest, or back.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;172&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Inform patients that hypoglycemia reported when systemic fluoroquinolones used in some patients receiving antidiabetic agents.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;171&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Advise patients with diabetes mellitus receiving oral antidiabetic agents or insulin to discontinue fluoroquinolone treatment and contact a clinician if they experience hypoglycemia or symptoms of hypoglycemia.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;171&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Inform patients that severe hepatotoxicity (including acute hepatitis and fatal events) reported in patients receiving moxifloxacin.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Importance of informing a clinician if any signs or symptoms of liver injury (e.g., loss of appetite, nausea, vomiting, fever, weakness, tiredness, right upper quadrant tenderness, itching, yellowing of the skin and eyes, light colored bowel movements, dark colored urine) occur.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Advise patients that diarrhea is a common problem caused by anti-infectives and usually ends when the drug is discontinued.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Importance of contacting a clinician if watery and bloody stools (with or without stomach cramps and fever) occur during or as late as 2 months or longer after the last dose.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of informing clinician of existing or contemplated concomitant therapy, including prescription and OTC drugs (e.g., drugs that may affect QT interval), as well as any concomitant illnesses.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of advising patients of other important precautionary information.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Cautions.)</p><h2 class="ddc-anchor-offset" id="preparations">Preparations</h2><p><i>Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.</i></p><p><i>Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.</i></p><p>* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name</p><p>Routes</p><p>Dosage Forms</p><p>Strengths</p><p>Brand Names</p><p>Manufacturer</p><p>Oral</p><p>Tablets, film-coated</p><p>400 mg of (of moxifloxacin)*</p><p>Avelox<sup></sup></p><p>Bayer</p><p>Moxifloxacin Hydrochloride Tablets</p><p>Parenteral</p><p>Injection, for IV infusion</p><p>400 mg (of moxifloxacin) in 0.8% sodium chloride*</p><p>Avelox<sup></sup> I.V.</p><p>Bayer</p><p>Moxifloxacin Hydrochloride Injection for IV Infusion</p><p>AHFS<sup></sup> DI Essentials™. © Copyright 2021, Selected Revisions August 26, 2019. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.</p><p>† Use is not currently included in the labeling approved by the US Food and Drug Administration.</p><h2>References</h2><p>1. Bayer Healthcare Pharmaceuticals, Inc. Avelox<sup></sup> (moxifloxacin hydrochloride) tablets and injection for IV use prescribing information. Whippany, NJ; 2019 May.</p><p>2. Zhanel GC, Ennis K, Vercaigne L et al. A critical review of the fluoroquinolones: focus on respiratory tract infections. <i>Drugs</i>. 2002. 62:13-59.</p><p>3. Blondeau JM. Expanded activity and utility of the new fluoroquinolones: a review. <i>Clin Ther</i>. 1999; 21:3-40. http://www.ncbi.nlm.nih.gov/pubmed/10090423?dopt=AbstractPlus</p><p>4. Stass H, Kubitza D. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. <i>J Antimicrob Chemother</i>. 1999; 43(Suppl):83B-90B.</p><p>5. Ballow C, Lettieri J, Agarwal V et al. Absolute bioavailability of moxifloxacin. <i>Clin Ther</i>. 1999; 21:513-22. http://www.ncbi.nlm.nih.gov/pubmed/10321420?dopt=AbstractPlus</p><p>6. Stass H, Dalhoff A, Kubitza D et al. Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. <i>Antimicrob Agents Chemother</i>. 1998; 42:2060-5. http://www.ncbi.nlm.nih.gov/pubmed/9687407?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=105860&amp;blobtype=pdf</p><p>7. Blondeau JM. A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new ‘respiratory quinolones’. <i>J Antimicrob Chemother</i>. 1999; 43(Suppl):1B-11B.</p><p>8. Reinert RR, Schlaeger JJ, Lëtticken R. Moxifloxacin: a comparison with other antimicrobial agents of in-vitro activity against <i>Streptococcus pneumoniae</i>. 1998; 42:803-6.</p><p>9. Buxbaum A, Straschil U, Moser C et al. Comparative susceptibility to penicillin and quinolones of 1385 <i>Streptococcus pneumoniae</i> isolates. <i>J Antimicrob Chemother</i>. 1999; 43(Suppl):13B-18B.</p><p>10. Man I, Murphy J, Ferguson J. Fluoroquinlone phototoxicity: a comparison of moxifloxacin and lomefloxacin in normal volunteers. <i>J Antimicrob Chemother</i>. 1999; 43(Suppl):B77-B82. http://www.ncbi.nlm.nih.gov/pubmed/10382879?dopt=AbstractPlus</p><p>11. Bayer Corporation, West Haven, CT: Personal communication.</p><p>12. US Food and Drug Administration. Janssen Pharmaceutica stops marketing cisapride in the U.S. FDA Talk Paper. Rockville, MD; 2000 March 23.</p><p>13. Parish LC, Routh HB, Miskin B et al. Moxifloxacin versus cephalexin in the treatment of uncomplicated skin infections. <i>Int J Clin Pract</i>. 2000; 54:497-503. http://www.ncbi.nlm.nih.gov/pubmed/11198726?dopt=AbstractPlus</p><p>20. Bishai W. Current issues on resistance, treatment guidelines, and the appropriate use of fluoroquinolones for respiratory tract infections. <i>Clin Ther</i>. 2002; 24:838-50. http://www.ncbi.nlm.nih.gov/pubmed/12117077?dopt=AbstractPlus</p><p>21. Bearden DT, Danziger LH. Mechanism of action of and resistance to quinolones. <i>Pharmacotherapy</i>. 2001; 21:224S-32S. http://www.ncbi.nlm.nih.gov/pubmed/11642689?dopt=AbstractPlus</p><p>23. Gillespie SH, Billington O. Activity of moxifloxacin against mycobacteria. <i>J Antimicrob Chemother</i>. 1999; 44:393-5. http://www.ncbi.nlm.nih.gov/pubmed/10511409?dopt=AbstractPlus</p><p>24. Woodcock JM, Andrews JM, Boswell FJ et al. In vitro activity of BAY 12-8039, a new fluoroquinolone. <i>Antimicrob Agents Chemother</i>. 1997; 41:101-6. http://www.ncbi.nlm.nih.gov/pubmed/8980763?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=163668&amp;blobtype=pdf</p><p>25. Valerio G, Bracciale P, Manisco V. Long-term tolerance and effectiveness of moxifloxacin therapy for tuberculosis: preliminary results. <i>J Chemother</i>. 2003; 15:77-70.</p><p>27. Zhanel GG, Palatnick L, Nichol KA et al. Antimicrobial resistance in respiratory tract <i>Streptococcus pneumoniae</i> isolates: results of the Canadian respiratory organism susceptibility study, 1997 to 2002. <i>Antimicrob Agents Chemother</i>. 2003; 47:1867-74. http://www.ncbi.nlm.nih.gov/pubmed/12760860?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=155828&amp;blobtype=pdf</p><p>28. Alvirez-Freites EJ, Carter JL, Cynamon MH. In vitro and in vivo activities of gatifloxacin against <i>Mycobacterium tuberculosis</i>. <i>Antimicrob Agents Chemother</i>. 2002; 46:1022-5. http://www.ncbi.nlm.nih.gov/pubmed/11897584?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=127120&amp;blobtype=pdf</p><p>29. Yang SC, Hsueh PR, Lai HC et al. High prevalence of antimicrobial resistance in rapidly growing mycobacteria in Taiwan. <i>Antimicrob Agents Chemother</i>. 2003; 47:1958-62. http://www.ncbi.nlm.nih.gov/pubmed/12760874?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=155839&amp;blobtype=pdf</p><p>32. Malangoni MA, Song J, Herrington J et al. Randomized controlled trial of moxifloxacin compared with piperacillin–tazobactam and amoxicillin–clavulanate for the treatment of complicated intra-abdominal infections. <i>Ann Surg</i>. 2006; 244:204-11. http://www.ncbi.nlm.nih.gov/pubmed/16858182?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=1602153&amp;blobtype=pdf</p><p>33. Sullivan JT, Woodruff M, Lettieri J et al. Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone. <i>Antimicrob Agents Chemother</i>. 1999; 43:2793-7. http://www.ncbi.nlm.nih.gov/pubmed/10543767?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=89563&amp;blobtype=pdf</p><p>34. Nightingale CH. Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics. <i>Pharmacotherapy</i>. 2000; 20:245-56. http://www.ncbi.nlm.nih.gov/pubmed/10730681?dopt=AbstractPlus</p><p>41. Goldstein EJC, Citron DM, Warren YA et al. In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections. <i>Antimicrob Agents Chemother</i>. 2006; 50:148-55. http://www.ncbi.nlm.nih.gov/pubmed/16377680?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=1346786&amp;blobtype=pdf</p><p>42. Betriu C, Rodriguez AI, Gomez M et al. Changing patterns of fluoroquinolone resistance among <i>Bacteroides fragilis</i> group organisms over a 6-year period (1997-2002). <i>Diagn Microbiol Infect Dis</i>. 2005; 53:221-3. http://www.ncbi.nlm.nih.gov/pubmed/16243476?dopt=AbstractPlus</p><p>44. Giordano P, Song J, Pertel P et al. Sequential intravenous/oral moxifloxacin versus intravenous piperacillin-tazobactam followed by oral amoxicillin-clavulanate for the treatment of complicated skin and skin structure infections. <i>Int J Antimicrob Agents</i>. 2005; 26:357-65. http://www.ncbi.nlm.nih.gov/pubmed/16229991?dopt=AbstractPlus</p><p>48. Rodriguez-Cerrato V, McCoig CC, Michelow IC et al. Pharmacodynamics and bactericidal activity of moxifloxacin in experimental <i>Escherichia coli</i> meningitis. <i>Antimicrob Agents Chemother</i>. 2001; 45:3092-7.</p><p>49. Rodriquez-Cerrato V, McCoig CC, Saavedra J et al. Garenoxacin (BMS-284756) and moxifloxacin in experimental meningitis caused by vancomycin-tolerant pneumococci. <i>Antimicrob Agents Chemother</i>. 2003; 47:211-5.</p><p>53. Anzueto A, Niederman MS, Pearle J et al. Community-acquired pneumonia recovery in the elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy. <i>Clin Infect Dis</i>. 2006; 42:73-81. http://www.ncbi.nlm.nih.gov/pubmed/16323095?dopt=AbstractPlus</p><p>54. Welte T, Petermann W, Schurmann D et al. Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy. <i>Clin Infect Dis</i>. 2005; 41:1697-705. http://www.ncbi.nlm.nih.gov/pubmed/16288390?dopt=AbstractPlus</p><p>55. Morganroth J, DiMarco JP, Anzueto A et al. A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia. <i>Chest</i>. 2005; 128:3398-406. http://www.ncbi.nlm.nih.gov/pubmed/16304291?dopt=AbstractPlus</p><p>56. Fogarty C, Torres A, Choudhri S et al. Efficacy of moxifloxacin for treatment of penicillin-, macrolide- and multidrug-resistant <i>Streptococcus pneumoniae</i> in community-acquired pneumonia. <i>Int J Clin Pract</i>. 2005; 59:1253-9. http://www.ncbi.nlm.nih.gov/pubmed/16236076?dopt=AbstractPlus</p><p>57. Niederman MS, Challenges in the management of community-acquired pneumonia: the role of quinolones and moxifloxacin. <i>Clin Infect Dis</i>. 2005; 41:S158-66.</p><p>58. Shams WE, Evans ME. Guide to selection of fluoroquinolones in patients with lower respiratory tract infections. <i>Drugs</i>. 2005; 65:949-91. http://www.ncbi.nlm.nih.gov/pubmed/15892589?dopt=AbstractPlus</p><p>60. Burman WJ, Goldberg S, Johnson JL et al. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. <i>Am J Respir Crit Care Med</i>. 2006; 174:331-8. http://www.ncbi.nlm.nih.gov/pubmed/16675781?dopt=AbstractPlus</p><p>61. Codecasa LR, Ferrara G, Ferrarese M et al. Long-term moxifloxacin in complicated tuberculosis patients with adverse reactions or resistance to first line drugs. <i>Respir Med</i>. 2006; 100:1566-72. http://www.ncbi.nlm.nih.gov/pubmed/16469488?dopt=AbstractPlus</p><p>64. Gandhi NR, Moll A, Sturm AW et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. <i>Lancet</i>. 2006; 368:1575-80. http://www.ncbi.nlm.nih.gov/pubmed/17084757?dopt=AbstractPlus</p><p>65. Johnson JL, Hadad DJ, Boom WH et al. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. <i>Int J Tuberc Lung Dis</i>. 2006; 10:605-12. http://www.ncbi.nlm.nih.gov/pubmed/16776446?dopt=AbstractPlus</p><p>66. Aubry A, Veziris N, Cambau E et al. Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of <i>Mycobacterium tuberculosis</i>: functional analysis of mutant enzymes. <i>Antimicrob Agents Chemother</i>. 2006; 50:104-12. http://www.ncbi.nlm.nih.gov/pubmed/16377674?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=1346799&amp;blobtype=pdf</p><p>67. Kam KM, Yip CW, Cheung TL et al. Stepwise decrease in moxifloxacin susceptibility amongst clinical isolates of multidrug-resistant <i>Mycobacterium tuberculosis</i>: correlation with ofloxacin susceptibility. <i>Microb Drug Resist</i>. 2006; 12:7-11. http://www.ncbi.nlm.nih.gov/pubmed/16584301?dopt=AbstractPlus</p><p>68. Somasundaram S, Paramasivan NC. Susceptibility of <i>Mycobacterium tuberculosis</i> strains to gatifloxacin and moxifloxacin by different methods. <i>Chemotherapy</i>. 2006; 52:190-5. http://www.ncbi.nlm.nih.gov/pubmed/16714850?dopt=AbstractPlus</p><p>69. Shandil RK, Jayaram R, Kaur P et al. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against <i>Mycobacterium tuberculosis</i>: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. <i>Antimicrob Agents Chemother</i>. 2007; 51:576-82. http://www.ncbi.nlm.nih.gov/pubmed/17145798?dopt=AbstractPlus</p><p>71. Granich RM, Oh P, Lewis B et al. Multidrug resistance among persons with tuberculosis in California, 1994-2003. <i>JAMA</i>. 2005; 293:2732-9. http://www.ncbi.nlm.nih.gov/pubmed/15941802?dopt=AbstractPlus</p><p>72. World Health Organization. Extensively drug-resistant tuberculosis (XDR-TB): recommendations for prevention and control. <i>Wkly Epidemiol Rec</i>. 2006; 45:430-2.</p><p>75. McDonald LC, Killgore GE, Thompson A et al. An epidemic, toxin gene-variant strain of <i>Clostridium difficile</i>. <i>N Engl J Med</i>. 2005; 353:2433-41. http://www.ncbi.nlm.nih.gov/pubmed/16322603?dopt=AbstractPlus</p><p>76. Loo VG, Poirier L, Miller MA et al. A predominantly clonal multi-institutional outbreak of <i>Clostridium difficile</i>-associated diarrhea with high morbidity and mortality. <i>N Engl J Med</i>. 2005; 353:2442-9. http://www.ncbi.nlm.nih.gov/pubmed/16322602?dopt=AbstractPlus</p><p>77. McDonald LC, Owings M, Jernigan DB. <i>Clostridium difficile</i> infection in patients discharged from US short-stay hospitals, 1996-2003. <i>Emerg Infect Dis</i>. 2006; 12:409-15. http://www.ncbi.nlm.nih.gov/pubmed/16704777?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=3291455&amp;blobtype=pdf</p><p>78. Bartlett JG, Peri TM. The new <i>Clostridium difficile</i>–what does it mean? <i>N Engl J Med</i>. 2005; 353:2503-5.</p><p>79. Centers for Disease Control and Prevention. Severe <i>Clostridium difficile</i>-associated disease in populations previously at low risk–four states, 2005. <i>MMWR Morb Mortal Wkly Rep</i>. 2005; 54:1201-5. http://www.ncbi.nlm.nih.gov/pubmed/16319813?dopt=AbstractPlus</p><p>80. Kazakova SV, Ware K, Baughman B et al. A hospital outbreak of diarrhea due to an emerging epidemic strains of <i>Clostridium difficile</i>. <i>Arch Intern Med</i>. 2006; 166:2518-24. http://www.ncbi.nlm.nih.gov/pubmed/17159019?dopt=AbstractPlus</p><p>81. Dhalla IA, Mamdani MM, Simor AE et al. Are broad-spectrum fluoroquinolones more likely to cause <i>Clostridium difficile</i>-associated disease? <i>Antimicrob Agents Chemother</i>. 2006; 50:3216-9.</p><p>82. Stass H, Kubitza D. Effects of iron supplements on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluroquinolone, in humans. <i>Clin Pharmacokinet</i>. 2001; 40 (suppl 1):57-62. http://www.ncbi.nlm.nih.gov/pubmed/11352443?dopt=AbstractPlus</p><p>83. Lettieri J, Vargas R, Agarwal V et al. Effect of food on the pharmacokinetics of a single oral dose of moxifloxacin 400 mg in healthy male volunteers. <i>Clin Pharmacokinet</i>. 2001; 40 (suppl 1):19-25 http://www.ncbi.nlm.nih.gov/pubmed/11352438?dopt=AbstractPlus</p><p>84. Stass H, Kubitza D. Effects of dairy products on the oral bioavailability of moxifloxacin, a novel 8-methoxyfuloroquinolone, in healthy volunteers. <i>Clin Pharmacokinet</i>. 2001; 40 (suppl 1):33-8. http://www.ncbi.nlm.nih.gov/pubmed/11352440?dopt=AbstractPlus</p><p>85. Ziganshina LE, Vizel AA, Squire SB. Fluoroquinolones for treating tuberculosis. <i>Cochrane Database Syst Rev</i>. 2005; Jul 20:CD004795.</p><p>86. Hori S, Kizu J, Kawamura M. Effects of anti-inflammatory drugs on convulsant activity of quinolones: a comparative study of drug interactions between quinolones and anti-inflammatory drugs. <i>J Infect Chemother</i>. 2003; 9:314-20. http://www.ncbi.nlm.nih.gov/pubmed/14691652?dopt=AbstractPlus</p><p>87. Ball P. Long-term use of quinolones and their safety. <i>Rev Infect Dis</i>. 1989; 11(Suppl 5):S1365-9. http://www.ncbi.nlm.nih.gov/pubmed/2672258?dopt=AbstractPlus</p><p>88. Davis GJ, McKenzie ME. Toxicologic evaluation of ofloxacin. <i>Am J Med</i>. 1989; 87(Suppl 6C):43S-46S. http://www.ncbi.nlm.nih.gov/pubmed/2690619?dopt=AbstractPlus</p><p>89. Mayer DG. Overview of toxicological studies. <i>Drugs</i>. 1987; 34(Suppl 1):150-3. http://www.ncbi.nlm.nih.gov/pubmed/3325258?dopt=AbstractPlus</p><p>90. Kato M, Onodera T. Morphological investigation of cavity formation in articular cartilage induced by ofloxacin in rats. <i>Fund Appl Toxicol</i>. 1988; 11:110-9.</p><p>91. Hooper DC, Wolfson JS. Fluoroquinolone antimicrobial agents. <i>N Engl J Med</i>. 1991; 324:384-94. http://www.ncbi.nlm.nih.gov/pubmed/1987461?dopt=AbstractPlus</p><p>92. Paton JH, Reeves DS. Fluoroquinolone antibiotics: microbiology, pharmacokinetics and clinical uses. <i>Drugs</i>. 1988; 36:193-228. http://www.ncbi.nlm.nih.gov/pubmed/3053126?dopt=AbstractPlus</p><p>93. Maggiolo F, Caprioli S, Suter F. Risk/benefit analysis of quinolone use in children: the effect on diarthrodial joints. <i>J Antimicrob Chemother</i>. 1990; 26:469-71. http://www.ncbi.nlm.nih.gov/pubmed/2254219?dopt=AbstractPlus</p><p>94. Pfister K, Mazur D, Vormann J et al. Diminished ciprofloxacin-induced chondrotoxicity by supplementation with magnesium and vitamin E in immature rats. <i>Antimicrob Agents Chemother</i>. 2007; 51:1022-7. http://www.ncbi.nlm.nih.gov/pubmed/17210779?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=1803142&amp;blobtype=pdf</p><p>95. Stahlmann R. Safety profile of the quinolones. <i>J Antimicrob Chemother</i>. 1990; 26(Suppl D):31-44. http://www.ncbi.nlm.nih.gov/pubmed/2286589?dopt=AbstractPlus</p><p>99. American Society of Health-System Pharmacists Commission on Therapeutics. ASHP therapeutic position statement on the preferential use of metronidazole for the treatment of <i>Clostridium difficile</i>-associated disease. <i>Am J Health-Syst Pharm</i>. 1998; 55:1407-11. http://www.ncbi.nlm.nih.gov/pubmed/9659970?dopt=AbstractPlus</p><p>101. Höffken G, Barth J, Rubinstein E et al. A randomized study of sequential intravenous/oral moxifloxacin in comparison to sequential intravenous ceftriaxone/oral cefuroxime axetil in patients with hospital-acquired pneumonia. <i>Infection</i>. 2007; 35:414-20. http://www.ncbi.nlm.nih.gov/pubmed/18034211?dopt=AbstractPlus</p><p>110. Bradley JS, Jackson MA, Committee on Infectious Diseases et al. The use of systemic and topical fluoroquinolones. <i>Pediatrics</i>. 2011; 128:e1034-45.</p><p>128. US Food and Drug Administration. FDA news. FDA requests boxed warnings on fluoroquinolone antimicrobial drugs. From FDA website. Accessed 2008 Sept 8. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116919.htm</p><p>129. US Food and Drug Administration. Information for healthcare professionals. FDA alert regarding fluoroquinolone antimicrobial drugs. 2008 Jul 8. From FDA website. Accessed 2008 Sept 8. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm126085.htm</p><p>130. US Food and Drug Administration. FDA drug safety communication: FDA requires label changes to warn of risk for possibly permanent nerve damage from antibacterial fluoroquinolone drugs taken by mouth or by injection. 2013 Aug 15. From FDA website. http://www.fda.gov/downloads/Drugs/DrugSafety/UCM365078.pdf</p><p>140. US Food and Drug Administration. FDA drug safety communication: FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur together. Silver Spring, MD; 2016 May 12. From FDA website. http://www.fda.gov/downloads/Drugs/DrugSafety/UCM500591.pdf</p><p>145. US Food and Drug Administration. FDA drug safety communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects. Silver Spring, MD; 2016 Jul 26. From FDA website. http://www.fda.gov/downloads/Drugs/DrugSafety/UCM513019.pdf</p><p>171. US Food and Drug Administration. FDA drug safety communication: FDA reinforces safety information about serious low blood sugar levels and mental health side effects with fluoroquinolone antibiotics; requires label changes. Silver Spring, MD; 2018 Jul 10. From FDA website. https://www.fda.gov/media/114192/download</p><p>172. US Food and Drug Administration. FDA drug safety communication: FDA warns about increased risk of ruptures or tears in the aorta blood vessel with fluoroquinolone antibiotics in certain patients. Silver Spring, MD; 2018 Dec 20. From FDA website. https://www.fda.gov/media/119532/download</p><p>192. Chow AW, Benninger MS, Brook I et al. IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. <i>Clin Infect Dis</i>. 2012; 54:e72-e112. http://www.ncbi.nlm.nih.gov/pubmed/22438350?dopt=AbstractPlus</p><p>193. Wald ER, Applegate KE, Bordley C et al. Clinical Practice Guideline for the Diagnosis and Management of Acute Bacterial Sinusitis in Children Aged 1 to 18 Years. <i>Pediatrics</i>. 2013: 132:e262-80.; :.</p><p>197. Anon. Drugs for bacterial infections. <i>Treat Guidel Med Lett</i>. 2010; 8:43-52. http://www.ncbi.nlm.nih.gov/pubmed/20489679?dopt=AbstractPlus</p><p>218. Nahid P, Dorman SE, Alipanah N et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. <i>Clin Infect Dis</i>. 2016; :.</p><p>231. World Health Organization. Treatment of tuberculosis guidelines. 4th ed. World Health Organization; 2010. From WHO website. http://apps.who.int/iris/bitstream/10665/44165/1/9789241547833_eng.pdf</p><p>276. World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis: 2016 update. From WHO website. http://www.who.int</p><p>292. American Academy of Pediatrics. Red Book: 2018–2021 Report of the Committee on Infectious Diseases. 31st ed. Itasca, IL: American Academy of Pediatrics; 2018.</p><p>293. Jackson MA, Schutze GE, Committee on Infectious Diseases. The Use of Systemic and Topical Fluoroquinolones. <i>Pediatrics</i>. 2016; 138 http://www.ncbi.nlm.nih.gov/pubmed/27940800?dopt=AbstractPlus</p><p>302. McDonald LC, Gerding DN, Johnson S et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). <i>Clin Infect Dis</i>. 2018; 66:987-994. http://www.ncbi.nlm.nih.gov/pubmed/29562266?dopt=AbstractPlus</p><p>303. Christ W, Lehnert T, Ulbrich B. Specific toxicologic aspects of the quinolones. <i>Rev Infect Dis</i>. 1988; 10(Suppl 1):S141-6. http://www.ncbi.nlm.nih.gov/pubmed/3279489?dopt=AbstractPlus</p><p>304. Fekety R for the American College of Gastroenterology Practice Parameters Committee. Guidelines for the diagnosis and management of <i>Clostridium difficile</i>-associated diarrhea and colitis. <i>Am J Gastroenterol</i>. 1997; 92:739-50. http://www.ncbi.nlm.nih.gov/pubmed/9149180?dopt=AbstractPlus</p><p>315. Kalil AC, Metersky ML, Klompas M et al. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. <i>Clin Infect Dis</i>. 2016; 63:e61-e111. http://www.ncbi.nlm.nih.gov/pubmed/27418577?dopt=AbstractPlus</p><p>344. Workowski KA, Bolan GA. Sexually Transmitted Diseases Treatment Guidelines, 2015. <i>MMWR Recomm Rep</i>. 2015; 64(RR-03):1-137. http://www.ncbi.nlm.nih.gov/pubmed/26042815?dopt=AbstractPlus</p><p>416. Tunkel AR, Hasbun R, Bhimraj A et al. 2017 Infectious Diseases Society of America's Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis. <i>Clin Infect Dis</i>. 2017; http://www.ncbi.nlm.nih.gov/pubmed/28203777?dopt=AbstractPlus</p><p>418. Tunkel AR, Hartman BJ, Kaplan SL et al. Practice guidelines for the management of bacterial meningitis. <i>Clin Infect Dis</i>. 2004; 39:1267-84. Updates may be available at IDSA website at www.idsociety.org. http://www.ncbi.nlm.nih.gov/pubmed/15494903?dopt=AbstractPlus</p><p>440. Panel on Opportunistic Infection in HIV-infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America (Accessed May 13, 2019). Updates may be available at HHS AIDS Information (AIDSinfo) website. http://www.aidsinfo.nih.gov</p><p>450. Baddour LM, Wilson WR, Bayer AS et al. Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association. <i>Circulation</i>. 2015; 132:1435-86. http://www.ncbi.nlm.nih.gov/pubmed/26373316?dopt=AbstractPlus</p><p>512. Mandell LA, Wunderink RG, Anzueto A et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. <i>Clin Infect Dis</i>. 2007; 44 Suppl 2:S27-72. Updates may be available at IDSA website at www.idsociety.org. http://www.ncbi.nlm.nih.gov/pubmed/17278083?dopt=AbstractPlus</p><p>543. Stevens DL, Bisno AL, Chambers HF et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. <i>Clin Infect Dis</i>. 2014; 59:147-59. http://www.ncbi.nlm.nih.gov/pubmed/24947530?dopt=AbstractPlus</p><p>544. Lipsky BA, Berendt AR, Cornia PB et al. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. <i>Clin Infect Dis</i>. 2012; 54:e132-73. Updates may be available at IDSA website at www.idsociety.org.</p><p>668. Inglesby TV, O’Toole T, Henderson DA et al for the Working Group on Civilian Biodefense. Anthrax as a biological weapon, 2002: updated recommendations for management. <i>JAMA</i>. 2002; 287:2236-52. http://www.ncbi.nlm.nih.gov/pubmed/11980524?dopt=AbstractPlus</p><p>671. Bradley JS, Peacock G, Krug SE et al. Pediatric anthrax clinical management. <i>Pediatrics</i>. 2014; 133:e1411-36. http://www.ncbi.nlm.nih.gov/pubmed/24777226?dopt=AbstractPlus</p><p>672. Meaney-Delman D, Zotti ME, Creanga AA et al. Special considerations for prophylaxis for and treatment of anthrax in pregnant and postpartum women. <i>Emerg Infect Dis</i>. 2014; 20:e1-6. http://www.ncbi.nlm.nih.gov/pubmed/24457117?dopt=AbstractPlus</p><p>673. Hendricks KA, Wright ME, Shadomy SV et al. Centers for disease control and prevention expert panel meetings on prevention and treatment of anthrax in adults. <i>Emerg Infect Dis</i>. 2014; 20 http://www.ncbi.nlm.nih.gov/pubmed/24447897?dopt=AbstractPlus</p><p>675. Griffith DE, Aksamit T, Brown-Elliott BA et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. <i>Am J Respir Crit Care Med</i>. 2007; 175:367-416. http://www.ncbi.nlm.nih.gov/pubmed/17277290?dopt=AbstractPlus</p><p>681. Centers for Disease Control and Prevention. Diagnosis and management of foodborne illnesses: a primer for physicians. <i>MMWR Recomm Rep</i>. 2001; 50(RR-2):1-69.</p><p>683. US Army Medical Research Institute of Infectious Disease. USAMRIID’s medical management of biologic casualties handbook. 8th ed. USAMRIID: Fort Detrick, MD; 2014 Sep.</p><p>686. Centers for Disease Control and Prevention. Update: investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy, October 2001. <i>MMWR Morb Mortal Wkly Rep</i>. 2001; 50:909-19. http://www.ncbi.nlm.nih.gov/pubmed/11699843?dopt=AbstractPlus</p><p>688. Inglesby TV, Dennis DT, Henderson DA et al for the Working Group on Civilian Biodefense. Plague as a biological weapon: medical and public health management. <i>JAMA</i>. 2000; 283:2281-90. http://www.ncbi.nlm.nih.gov/pubmed/10807389?dopt=AbstractPlus</p><p>708. Solomkin JS, Mazuski JE, Bradley JS et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2010; 50:133-64. http://www.ncbi.nlm.nih.gov/pubmed/20034345?dopt=AbstractPlus</p><p>767. Brookmeyer R, Johnson E, Bollinger R. Modeling the optimum duration of antibiotic prophyalxis in an anthrax outbreak. <i>Proc Natl Acad Sci</i>. 2003; 100:10129-32. http://www.ncbi.nlm.nih.gov/pubmed/12890865?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=187789&amp;blobtype=pdf</p><p>HID. ASHP’s interactive handbook on injectable drugs. McEvoy, GK, ed. Bethesda, MD: American Society of Health-System Pharmacists, Inc; Updated July 2, 2018. From HID website. http://www.interactivehandbook.com/</p><h2>More about moxifloxacin</h2><ul class="more-resources-list more-resources-list-general">
<li>Side Effects</li>
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>195 Reviews</li>
<li>Drug class: quinolones</li>
<li>FDA Alerts (6)</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Moxifloxacin &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;span&gt;(Advanced Reading)&lt;/span&gt;&lt;/body&gt;&lt;/html&gt;</li>
<li>Moxifloxacin Intravenous &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;span&gt;(Advanced Reading)&lt;/span&gt;&lt;/body&gt;&lt;/html&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li>Moxifloxacin Injection &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;span&gt;(FDA)&lt;/span&gt;&lt;/body&gt;&lt;/html&gt;</li>
<li>Moxifloxacin Tablets &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;span&gt;(FDA)&lt;/span&gt;&lt;/body&gt;&lt;/html&gt;</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Bacterial Infection</li>
<li>Anthrax</li>
<li>Anthrax Prophylaxis</li>
<li>Bronchitis</li>
<li data-more-config-id="list-data-resources-conditions">... +10 more</li>
</ul><p class="ddc-disclaimer-link">Medical Disclaimer</p></body></html>